U.S. Markets closed

Adverum Biotechnologies, Inc. (ADVM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.3600-0.7000 (-22.88%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.0600
Open2.4900
Bid2.3300 x 800
Ask2.3600 x 1400
Day's Range2.2550 - 2.5500
52 Week Range2.2550 - 19.2500
Volume9,839,508
Avg. Volume3,270,114
Market Cap231.126M
Beta (5Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-1.3500
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.88
  • Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema
    GlobeNewswire

    Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema

    -- Based on latest analyses, company is revising ADVM-022 development plan to focus on wet AMD and low doses (2 x 10^11 vg/eye and lower); no longer planning development for DME -- -- Company to host conference call and webcast today at 1:30 pm PT / 4:30 pm ET -- REDWOOD CITY, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today provided an update on the ADVM-

  • Hedge Funds Are Cashing Out Of Adverum Biotechnologies, Inc. (ADVM)
    Insider Monkey

    Hedge Funds Are Cashing Out Of Adverum Biotechnologies, Inc. (ADVM)

    The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F filings […]

  • Adverum Announces Appointment of Jon Williams, Ph.D., as Vice President, Clinical Affairs
    GlobeNewswire

    Adverum Announces Appointment of Jon Williams, Ph.D., as Vice President, Clinical Affairs

    REDWOOD CITY, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Jon Williams, Ph.D., as vice president, clinical affairs, effective immediately. Dr. Williams will provide scientific and technical expertise and leadership across Adverum’s clinical development program for ADVM-022, reporting to Julie Clark, M.D., chief medical off